Latham & Watkins Advises Sight Sciences in Initial Public Offering

Sight Sciences, Inc., a growth-stage medical device company focused on the development and commercialization of proprietary devises that target the underlying causes of the world’s most prevalent eye diseases, has announced the pricing of its initial public offering of 10,000,000 shares of common stock at a public offering price of US$24 per share. All shares of common stock are being offered by Sight Sciences for total gross proceeds of US$240 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Sight Sciences has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Sight Sciences’ common stock is trading on the Nasdaq Global Market under the ticker symbol SGHT. The offering is expected to close on July 19, 2021, subject to the satisfaction of customary closing conditions.

Latham & Watkins LLP represents Sight Sciences, Inc. in the offering with a capital markets team led by partners Peter Handrinos and Wesley Holmes, with associates Valerie Lau, Danny Shulman, and Ashley Petrarca.